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OBJECTIVE — There are conﬂicting data regarding relationships of systemic biomarkers of
inﬂammation, hemostasis, and homocysteine with diabetic retinopathy. We examined these
relationships in the Multi-Ethnic Study of Atherosclerosis.
RESEARCH DESIGN AND METHODS — A total of 921 participants with diabetes
were included. Diabetic retinopathy was graded from retinal photographs. We deﬁned two
outcomes: any diabetic retinopathy and vision-threatening diabetic retinopathy (severe nonpro-
liferative diabetic retinopathy or worse). Systemic markers analyzed were C-reactive protein,
homocysteine, ﬁbrinogen, plasmin-2-antiplasmin complex (PAP), interleukin-6, D-dimer, fac-
tor VIII, serum creatinine, and urinary albumin-to-creatinine (UAC) ratio.
RESULTS — Prevalence of diabetic retinopathy was 33.2% and vision-threatening diabetic
retinopathy 7.1%. After adjusting for established risk factors (diabetes duration, A1C, systolic
blood pressure, waist-to-hip ratio, and use of diabetes medications), ﬁbrinogen (odds ratio 1.14
[95% CI 1.01–1.32], P  0.05) and PAP (1.25 [1.05–1.50], P  0.01) were associated with any
diabetic retinopathy, while PAP (1.54 [1.13–2.11], P  0.007) and homocysteine (1.57 [1.16–
2.11], P  0.003) were associated with vision-threatening diabetic retinopathy. Only PAP
remainedsigniﬁcantafteradditionaladjustmentforserumcreatinineandUACratio.Areaunder
receiver-operator characteristic curve (AUROC) for diabetic retinopathy was constructed for
established and novel risk factors. Established risk factors accounted for a 39.2% increase of the
AUROC, whereas novel markers (ﬁbrinogen, PAP, homocysteine, serum creatinine, and UAC
ratio) only accounted for an additional 2.2%.
CONCLUSIONS — There were few associations of novel markers of inﬂammation, hemo-
stasis, and homocysteine with diabetic retinopathy after controlling for established risk factors.
These data suggest that there is limited clinical use of these biomarkers for prediction of diabetic
retinopathy.
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D
iabetic retinopathy is the leading
cause of blindness in working-age
individuals (1). There is increasing
evidence that established risk factors for
diabetic retinopathy (2,3), including du-
rationofdiabetes,hyperglycemia,andhy-
pertension,onlyexplainalimitedamount
of the variance in the risk of diabetic ret-
inopathy (1). Furthermore, the underly-
ing pathogenesis of diabetic retinopathy
remains inadequately understood (4).
This has resulted in examination of the
relation of novel risk markers such as in-
ﬂammation (e.g., C-reactive protein
[CRP]), markers of hemostatic distur-
bances (e.g., ﬁbrinogen levels), and
hyperhomocysteinemia to diabetic reti-
nopathy. However, to date, the relations
of these factors to diabetic retinopathy
have not been consistent (5–17). The rea-
sonsfortheseinconsistenciesmaybedue,
in part, to differences in study sample
and deﬁnitions of diabetic retinopathy
(e.g., clinical versus photograph grading)
and failure in some studies to make ade-
quate adjustments for traditional risk fac-
tors such as glycemic control and
hypertension. Thus, it remains unclear if
there is a role for the use of these systemic
markers as additional clinical tests to
identify individuals at high risk of dia-
betic retinopathy. In this study, we eval-
uated the relationship of a range of
inﬂammatory, hemostatic, and novel vas-
cular markers with diabetic retinopathy,
while controlling for traditional risk fac-
tors, in a large multiethnic population.
RESEARCH DESIGN AND
METHODS— The Multi-Ethnic Study
of Atherosclerosis (MESA) is a popula-
tion-basedstudyofmenandwomenaged
45–84 years comprising four racial/
ethnic groups (whites, blacks, Hispanics,
and Chinese). Participants have no his-
tory of clinical cardiovascular disease at
baselineandareresidentsofsixU.S.com-
munities (18). Tenets of the Declaration
of Helsinki were followed, and institu-
tional review board approval was granted
at each study site. Written informed con-
sent was obtained from all participants.
There were 6,814 participants at the
ﬁrst examination (from July 2000 to Au-
gust 2002). Retinal photography was
done at the second examination, which
immediately followed the baseline exam-
ination (from August 2002 to January
2004). A total of 6,237 participants re-
turned for retinal photography, of whom
6,147 had digital images gradable for
retinopathy. Of these, 921 participants
had diabetes, deﬁned as fasting glucose
7.0 mmol/l (126 mg/dl) and/or use
of insulin and/or oral hypoglycemic
medication.
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Diabetic retinopathy assessment has been
previouslypublished(19).Foreacheye,a
diabeticretinopathyseverityscorewasas-
signed based on modiﬁcation of the Airlie
House classiﬁcation system (20). We de-
ﬁned “any diabetic retinopathy” as level
14 (any combination of deﬁnite hard ex-
udates,cottonwoolspots,intraretinalmi-
crovascular abnormalities, and/or venous
loops in the absence of deﬁnite microan-
eurysms) and above and “vision-
threateningdiabeticretinopathy”aslevels
51 (microaneurysms and one or more of
the following: venous beading, hemor-
rhages or microaneurysms more than or
equaltotheEarlyTreatmentDiabeticRet-
inopathy Study standard photograph 2A
[20 retinal hemorrhages], or intrareti-
nal microvascular abnormalities more
than or equal to the Early Treatment Dia-
betic Retinopathy Study standard photo-
graph 8A [prominent]) to 80 (total
vitreoushemorrhage)orpresenceofmac-
ular edema. A subject’s diabetic retinopa-
thy level was based on the score of the
worse eye. Interobserver variation for exact
agreement for the 17-step diabetic retinop-
athy severity scale  score varied from 0.68
to 0.86, and for intraobserver variation for
100% agreement the  score varied from
0.68 to 0.91.
Assessment of other risk factors
A detailed questionnaire was used to ob-
tain participant information, including
past medical history, current cigarette
smoking, and current alcohol consump-
tion status. Hypertension was deﬁned as
systolic blood pressure (SBP) 140
mmHg, diastolic blood pressure 90
mmHg, or current use of antihyperten-
sivemedications.Restingbloodpressure
was measured three times in the seated
position using a Dinamap Model Pro
100 automated oscillometric sphygmo-
manometer (Critikon, Tampa, FL). The
average of the last two measurements was
used in analysis. Height and weight were
measured to determine BMI.
Fasting (8 h) blood samples were
drawn from participants, and aliquots
were prepared for central analysis and for
storage (65 aliquots per participant at
the ﬁrst examination) at the University of
Vermont and the University of Minnesota
(18). Standardized protocols were de-
signed to allow several domains of study
to be addressed, including measurements
of lipids and lipoproteins, systemic in-
ﬂammation, and endothelial cell function
(21). Details of these methods, including
coefﬁcients of variation, are provided
elsewhere (21). The following were ana-
lyzedinthisreport:plasmatotalandHDL
cholesterol, plasma triglycerides, plasma
A1C, plasma plasmin-2-antiplasmin
complex (PAP), plasma D-dimer, plasma
factor VIII, plasma total homocysteine,
serumglucose,serumhigh-sensitiveCRP,
serum ﬁbrinogen, serum interleukin
(IL)-6, serum creatinine, and the urinary
albumin-to-creatinine (UAC) ratio.
Statistical analysis
Baseline characteristics of participants
with and without diabetic retinopathy
were compared using 
2 test for propor-
tions, t test, or Mann-Whitney U test for
means. Logistic regression models were
constructed and initial model was ad-
justed for age, sex, race, and study center.
The risk factors that were signiﬁcant in
theinitialmodelwerefurtheradjustedfor
confounders previously found to be inde-
pendently associated with diabetic reti-
nopathy in the MESA (19) (SBP, use of
diabetes medications, duration of diabe-
tes, A1C, and waist-to-hip ratio [model
1]). Further adjustments were made for
UAC ratio alone (model 2) and then UAC
ratio and serum creatine combined
(model 3). Area under the receiver-
operator characteristic curve (AUROC)
for diabetic retinopathy were constructed
for each of the established and novel risk
factors,andthepercentageoftheincremen-
tal changes in AUROC (in addition to age
and sex) were presented to determine the
use of the various traditional and novel risk
factors for diabetic retinopathy prediction.
Analyses were performed using SPSS ver-
sion 16.0.1 (SPSS, Chicago, IL).
RESULTS— Among participants with
diabetes, the prevalence of any diabetic
Table 1—Characteristics of 921 participants with diabetes, the MESA
No retinopathy Diabetic retinopathy P*
n 643 278
Sex (male) 51.9 52.1 0.96
Race 0.01
White 24.6 16.2
African American 33.7 40.3
Hispanic 28.6 33.1
Chinese 13.1 10.4
History of alcohol consumption 38.4 34.7 0.26
Current cigarette smoker 11.4 10.1 0.56
Hypertension 71.7 76.8 0.09
Use of oral diabetes medication 47.2 55.5 0.001
Use of insulin 5.9 21.5 0.001
Age (years) 65.3  9.2 65.0  9.2 0.60
Serum glucose (mg/dl) 148.5  49.0 166.1  63.4 0.001
SBP (mmHg) 129.3  20.0 133.9  24.9 0.003
Diabetes duration (years)† 0 (5) 7 (15) 0.001
A1C (%) 7.03  1.44 7.78  1.85 0.001
BMI (kg/m
2) 30.9  6.12 30.6  5.96 0.43
Plasma total cholesterol (mg/dl) 181.5  36.4 182.6  38.6 0.70
HDL cholesterol (mg/dl) 46.2  12.9 47.2  12.7 0.25
Triglycerides (mg/dl) 163.5  119.6 148.2  101.2 0.06
CRP (mg/dl)† 2.6 (4.7) 2.5 (4.7) 0.66
Plasma ﬁbrinogen (mg/dl) 360  79.2 370  81.1 0.006
PAP (nmol/l)† 4.0 (1.9) 4.4 (2.4) 0.001
IL-6 (pg/ml)† 1.5 (1.3) 1.5 (1.4) 0.83
D-Dimer (ug/ml)† 0.2 (0.3) 0.2 (0.2) 0.96
Factor VIII (%) 184  72.5 187  80.9 0.60
Creatinine (mg/dl)† 0.9 (0.2) 0.9 (0.4) 0.24
UAC ratio (mg/dl)† 8.6 (16.3) 14.9 (48.5) 0.001
Homocysteine (	mol/l)† 8.8 (3.7) 8.9 (3.4) 0.58
Data are percent, means  SD, or median (interquartile range). Data were obtained during the ﬁrst exami-
nation (from July 2000 to August 2002), except for retinopathy, which was collected during the second
examination(fromAugust2002toJanuary2004).*Pvaluebasedon
2(categorical),ttest(quantitativeand
normal), or Mann-Whitney U test (quantitative and skewed), comparing diabetes participants with and
without retinopathy. †Results are shown as median (interquartile range) for skewness.
Nguyen and Associates
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lence of vision-threatening diabetic reti-
nopathy 7.9%. Participants with diabetic
retinopathy were more likely to have a
history of use of insulin and/or oral hypo-
glycemic medications, higher SBP, higher
serum glucose, higher A1C, and longer
duration of diabetes than those without
diabetic retinopathy (Table 1). There
were also higher proportions of African
Americans and Hispanics with diabetic
retinopathy than Caucasians and Chinese
Americans(wehavepreviouslypublished
the detailed analysis of prevalence of dia-
beticretinopathyintheMESApopulation
[19]).
Table 1 also shows that individuals
with diabetic retinopathy had higher lev-
els of plasma ﬁbrinogen (370  81.1 vs.
360  79.2 mg/dl, P  0.006), PAP
(4.4  2.4 vs. 4.0  1.9 nmol/l, P 
0.001), and UAC ratio (14.9  48.5 vs.
8.6  16.3, P  0.001) than those with-
out diabetic retinopathy. CRP, IL-6, D-
dimer, factor VIII, creatinine, and
homocysteine were not associated with
the presence of diabetic retinopathy.
After adjustment for age, sex, race,
study center, SBP, use of diabetes medi-
cations, duration of diabetes, A1C, and
waist-to-hip ratio, ﬁbrinogen (odds ratio
1.14 [95% CI 1.01–1.32], P  0.05) and
PAP (1.25 [1.05–1.50], P  0.01) were
associated with any diabetic retinopathy,
while PAP (1.54 [1.13–2.11], P  0.007)
and homocysteine (1.57 [1.16–2.11],
P  0.003) were associated with vision-
threatening diabetic retinopathy (Table
2). These associations remained after ad-
ditional adjustment for UAC ratio. How-
ever, after further adjustment of serum
creatinine level, only PAP remained asso-
ciatedwithanydiabeticretinopathy(1.28
[1.07–1.54], P  0.008) or vision-
threatening diabetic retinopathy (1.51
[1.10–2.08], P  0.01). Further stratiﬁ-
cation by above/below 65 years of age did
not change the associations observed in
the two age-groups (data not shown).
Table 3 shows the AUROC for the
prediction of diabetic retinopathy with
traditional and novel risk factors for dia-
betic retinopathy. Each variable was
added to age and sex separately to deter-
mine the AUROC for that variable (and
age and sex). The total change (%) in the
AUROC for the traditional risk factors is
39.2%, while for novel risk factors it is
23.3%.Figure1isaVenndiagramusedto
illustrate the relationship of the change
in the AUROC for diabetic retinopathy
between the traditional and novel risk
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traditional risk factors alone is 18.1% and
the novel risk factors alone is 2.2%, while
the inseparable (or “overlap”) change of
traditional and novel risk factors is
21.1%.
CONCLUSIONS — Our study dem-
onstrated an association of plasma ﬁbrin-
ogen, PAP, and homocysteine with
diabetic retinopathy; however, only the
association of PAP with diabetic retinop-
athy was independent of the traditional
risk factors for diabetic retinopathy, such
as duration of diabetes, SBP, A1C, serum
creatinine, and UAC ratio. Furthermore,
the incremental contribution of these
novel risk factors (ﬁbrinogen, PAP, ho-
mocysteine, and the UAC ratio) to dia-
betic retinopathy risk is small. The AUC
with traditional risk factors accounted for
36.8%ofthevariationofdiabeticretinop-
athy, and the addition of novel markers
only accounted for an additional 1.4%.
Thus, these analyses suggest there is lim-
ited clinical use with the addition of these
systemic biomarkers for diabetic retinop-
athy prediction.
We found an association of homocys-
teine with vision-threatening diabetic ret-
inopathy, but this was attenuated and no
longersigniﬁcantafterfurtheradjustment
for serum creatinine and UAC ratio. This
is consistent with data from some other
studies (9–11,16). In studies in which an
association between presence of diabetic
retinopathy and elevated homocysteine
has been reported previously, serum cre-
atinine and UAC ratio were not included
in the statistical analyses (7,8,15). Our
study therefore suggests that part of the
associationofhomocysteinewithdiabetic
retinopathy was related to concurrent di-
abetic nephropathy.
Our study found a signiﬁcant rela-
tionshipofPAPwithanydiabeticretinop-
athy and vision-threatening diabetic
retinopathy. Le et al. (17) did ﬁnd in-
creased PAP with diabetic retinopathy,
but the result was no longer signiﬁcant
after multivariable adjustment. The rela-
tionship in our study could be a conse-
quence of increased sample size (921
vs. 104) and/or older age of the MESA
participants (mean 52.0 vs. 32.0 years).
D-Dimer and PAP are markers of ﬁbrino-
lysis. Procoagulant reactions producing
ﬁbrin activate ﬁbrinolysis to produce
plasmin, which degrades ﬁbrin to pro-
duce D-dimer. PAP is formed by the bind-
ing to and inactivation of free plasmin by
its inhibitor, 2-antiplasmin; therefore,
the PAP level measures recent plasmin
production(22).Inaddition, D-dimerand
PAP appear to measure different aspects
of ﬁbrinolysis, as their predictive abilities
of myocardial infarction and coronary
deaths have previously been shown to be
independentofeachother(23).Similarly,
D-dimer, unlike PAP, was not elevated in
those with diabetic retinopathy in our
study. However, further conﬁrmation of
our ﬁnding, as well as its signiﬁcance, is
needed.
While inﬂammation has been consid-
ered to be a pathogenic factor in the de-
velopment and progression of diabetic
retinopathy (24), associations of systemic
markers of inﬂammation, such as serum
CRP, with diabetic retinopathy have been
Figure 1—Venn diagram to illustrate the relationship of the change (%) in the AUROC for
diabetic retinopathy of the predictive models between traditional and novel risk factors. Circle A:
Traditional/establishedriskfactors:39.2%.CircleB:Novelriskfactors:23.3%.ABintersection
of circles A and B: Inseparable effect of traditional/established and novel risk factors: 21.1%.
Traditional/established risk factors alone: 18.1%. Novel risk factors alone: 2.2%.
Table 3—AUROC for diabetic retinopathy of the predictive models that include traditional
and novel risk factors
AUROC for diabetic retinopathy
AUROC
Change (%) in
AUROC*
Model 1: age/sex adjusted 0.541 —
Model 2†
Duration of diabetes 0.717 32.5
Diabetes medications 0.668 23.5
A1C 0.640 18.3
SBP 0.574 6.1
Waist-to-hip ratio 0.569 5.2
Traditional/established risk factors† 0.753 39.2
Model 2†
UAC ratio 0.643 18.9
PAP 0.596 10.2
Fibrinogen 0.574 6.1
Homocysteine 0.543 0.4
Serum creatinine 0.543 0.4
Novel risk factors‡ 0.667 23.3
Traditional and novel risk factors§ 0.765 41.4
Data were obtained during the ﬁrst examination (from July 2000 to August 2002) except for retinopathy,
which was collected during the second examination (from August 2002 to January 2004).*Percent increase
of AUROC  AUROC of model 2 
 AUROC model 1  100 AUROC model 1.†Each variable was added
separatelytoageandsex.TheAUROCofeachrowisthatofthevariable,age,andsexinthemodelonly.‡The
combined change of the AUROC for the traditional/established risk factors (i.e., duration of diabetes, use of
diabetes medications, A1C, SBP, and waist-to-hip ratio) or the novel risk factors (i.e., UAC ratio, PAP,
ﬁbrinogen, homocysteine, and serum creatinine). §The combined change of the AUROC for the traditional/
established and novel risk factors.
Nguyen and Associates
DIABETES CARE, VOLUME 32, NUMBER 9, SEPTEMBER 2009 1707inconsistently reported in some studies
(12,13) but not others (5,6,17). Our
study also showed that common systemic
markers of inﬂammation, such as CRP
and IL-6, were not associated with dia-
betic retinopathy. Possible differences in
the ﬁndings among studies are likely re-
lated to differences in type of diabetes,
sample sizes, or inadequately controlling
for confounding factors. For example,
Schram et al. (6) examined 543 subjects
with type 1 diabetes but did not control
for presence of hypertension and ne-
phropathy, while Van Hecke et al.(5) ex-
amined 192 subjects with type 2 diabetes
anddidnotcontrolforpresenceofhyper-
tension, nephropathy, duration of diabe-
tes, and A1C. In our study, we were able
to adjust for not only traditional risk fac-
tors for diabetic retinopathy such as du-
ration of diabetes, SBP, and A1C but also
serum creatinine, although no distinction
was made between type 1 and type 2 di-
abetes in the MESA. In addition, while
there is evidence that inﬂammatory
changes may be involved with the patho-
genesis of diabetic retinopathy in the eye,
thelackofﬁndingsucharelationbetween
systemicmarkersofinﬂammationanddi-
abetic retinopathy in our study and other
studies may reﬂect the fact that due to the
presence of the retinal-blood barrier,
higher levels of inﬂammatory markers
such as IL-6 found in the vitreous in pa-
tients with diabetic retinopathy are not
seen in the systemic circulation.
In addition, our ﬁnding of a lack of
association between diabetic retinopathy
and ﬁbrinogen levels that was indepen-
dent of traditional risk factors should be
compared with two previous studies
(14,25) that have also found no associa-
tion. Of these studies, one involved 92
subjects with type 2 diabetes (25), while
theotherstudied909subjectswithtype1
diabetes from the Diabetes Control and
Complication Trial/Early Treatment Dia-
betic Retinopathy Study cohort (14). In a
recent study of 104 Pima Indian partici-
pants, an association was found between
ﬁbrinogen level and diabetic retinopathy
(17). However, the participants in this
study were younger (mean age 32 years),
andthestatisticalanalysisdidnotaccount
for glycemic control, blood pressure, and
serum creatinine.
Analysis by using the AUROC shows
thatthereisan“overlapping”oftheeffects
of the predictive models for diabetic reti-
nopathyusingtraditional/establishedand
novel risk factors. This illustrates the
complex relationship between the factors
anddiabeticretinopathy.Itisconceivable
thatthenovelriskmarkerscanalsobethe
underlying pathological mechanisms of
the traditional risk factors of diabetic ret-
inopathy, such as abnormal hemostasis
and elevated homocysteinemia may be
due to prolonged hyperglycemia (i.e.,
longer duration of diabetes and poor dia-
betes and blood pressure control).
The strengths of this study include a
large population-based sample and the
assessment of diabetic retinopathy by
standardized grading protocols. Limita-
tions of this study should also be noted.
First, the cross-sectional nature of the
study limits ability to judge temporal se-
quence of associations. Second, the fail-
ure to ﬁnd associations with these novel
markers may be due to survival bias. We
obtained 45° nonstereoscopic, nonmyd-
riatic photographs to grade diabetic reti-
nopathy, which is less sensitive than
grading from seven ﬁelds of stereoscopic
fundus photographs, and therefore we
could have underestimated the propor-
tion with diabetic retinopathy in our
study population. Finally, the key to pre-
dicting tissue injury in diabetes is testing
for the correct molecules, and therefore
future knowledge gained from, for exam-
ple, proteomic expression studies of in-
ﬂammatory markers may yield new
insights.
In conclusion, this study shows that
novel systemic biomarkers of inﬂamma-
tion and hemostasis and homocysteine
are not consistently or strongly related to
diabetic retinopathy independently of es-
tablished risk factors. These data suggest
limited clinical use of these biomarkers
for diabetic retinopathy prediction.
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